Medical cannabis and the first CBD limits, 2019
February 2019 opened medical cannabis research in Thailand. August 2019 is the first time a CBD percentage, 99% CBD and 0.01% THC, took something off Category 5.
Medical research, then the first CBD carve-out
Narcotics Act (No. 7), in force 19 February 2019, is the amendment that allows medical research and production under licence. It is also the day clauses 1 and 2 of the cannabis patent order end. [1] [2]
On 31 August 2019 the plant is still Category 5. Off the list: hemp as separately defined; CBD extracted from cannabis at 99% or more purity and not over 0.01% THC; a CBD-dominant extract or product at not over 0.2% THC that is a drug or a herbal product and is used as one; and dried bark, stalk core, and fibre. For five years the extract exceptions apply only to domestic production by a licensee. Hemp has the same 99% and 0.2% rules, plus non-viable seed, seed oil used as food, and seed oil or seed extract used as a cosmetic. [3]
The 14 December 2020 notification repeals that list by name. [4] [3]
| Instrument | Signed | Gazette | In force | ||
|---|---|---|---|---|---|
| 1 | Narcotics Act (No. 7) B.E. 2562 The amendment that opened medical research and ended clauses 1 and 2 of the NCPO patent order. | — | — | 19 February 2019 | |
| 2 | NCPO Order 1/2562 | 28 January 2019 Prayut Chan-o-cha | 28 January 2019 136, special 25 ง, pp. 92–94 | 28 January 2019 | |
| 3 | Category 5 notification (No. 2) B.E. 2562 First numeric CBD carve-out. Repealed by the 14 December 2020 list. | 27 August 2019 | 30 August 2019 | 31 August 2019 | |
| 4 | Category 5 notification B.E. 2563 Domestic extract at not over 0.2% THC, and hemp seed, leave the list. The plant stays on it. | — | 14 December 2020 | 15 December 2020 |